A Phase 4 interventional study of bosentan and placebo in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one has the largest enrollment, is one of 3 that started in 2006, is one of 5 in phase 4, and was the 2nd registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →
Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 8 · Phase 4 5
First in 2003; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 334 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 37 across the 18 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 9 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 6th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2006, is one of 11 in phase 4, and was the 5th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH already receiving sildenafil therapy. Patients must have been receiving doses of sildenafil equal to or greater than 20 mg t.i.d. for at least 12 weeks prior to being randomized.
The study continued until the predefined target number of morbidity/mortality events was reached.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males or females >=12 years of age (except for countries where this age limit is contrary to specific regulatory requirements).
·Reliable methods of contraception are:
O Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in combination with a spermicide.
O Intrauterine devices. O Oral, transdermal, injectable or implantable contraceptives only in combination with a barrier method.
Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception.
Patients with the following types of PAH belonging to WHO Group I:
Associated with (APAH):
i. Collagen vascular disease with normal left ventricular function ( (EF) > 50%) ii. Congenital systemic-to-pulmonary shunts at least 2 years post surgical repair iii. Drugs and toxins
PAH diagnosed by right heart catheter showing:
Exclusion Criteria :
Concomitant systemic treatment within 1 week prior to randomization with
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bosentan
Drug: bosentan
Placebo
Drug: placebo
bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
Matching bosentan placebo/b.i.d.
Time to First Confirmed Morbidity/Mortality Event up to the End of Study
Kaplan-Meier estimate of percentage of participants without a morbidity/mortality event. A morbidity/mortality event is defined as the occurrence of a) death, b) hospitalization for worsening or complication of PAH or intravenous prostanoid initiation, c) atrial septostomy, d) lung transplantation, or e) worsening PAH, defined as "moderately" or "markedly" worsened PAH symptoms using a patient global self-assessment (PGSA) scale AND initiation of inhaled or subcutaneous prostanoids or the disease progression package (open-label bosentan). If a patient replied "no change" or "mildly worse" on the PGSA, a decrease in 6MWT of 20% versus last visit or 30% versus baseline is also required to confirm the event.
Time frame: From baseline to end of study, approximately 86 months
Time to First Confirmed Death, Hospitalization for Worsening or Complication of PAH or Initiation of Intravenous Prostanoids, Atrial Septostomy, or Lung Transplantation
Kaplan-Meier estimate of percentage of participants without an event of death, hospitalization (for worsening or complication of PAH or initiation of intravenous prostanoids), atrial septostomy or lung transplantation. Time to first confirmed death, hospitalization (for worsening or complication of PAH or initiation of intravenous prostanoids), atrial septostomy or lung transplantation from baseline to end of study was confirmed by an independent Clinical Endpoint Committee.
Time frame: Baseline to end of study, approximately 86 months
Change From Baseline to Week 16 in 6 Minute Walk Test (6MWT)
The 6MWT is a non-encouraged test, which measures the distance covered over a 6 minute walk; the patient is instructed to walk as far as possible in a 30 m long flat corridor, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Areas were to be well ventilated with air temperature controlled between 20 °C and 23 °C (68 °F to 76 °F). The test was to be administered at the same time of day and by the same tester throughout the study. The tester measured the distance walked by non-encouraged patients during the timed 6 minute period.
Time frame: From baseline to week 16
Number of Participants With Improved, No Change, or Worsened World Health Organisation Functional Class From Baseline to Week 16
Class I: no limitation of usual physical activity (PA) which does not increase dyspnea, fatigue, chest pain, or presyncope. Class II: mild limitation of PA. No discomfort at rest. Normal PA increases dyspnea, fatigue, chest pain, or presyncope. Class III: marked limitation of PA. No discomfort at rest. Less than ordinary activity increases dyspnea, fatigue, chest pain, or presyncope. Class IV: unable to perform any PA and who may have signs of right ventricular failure. Dyspnea and/or fatigue may be present at rest and symptoms are increased by almost any PA.
Time frame: From baseline to Week 16
Time to Death of All Causes From Baseline to End of Study
Kaplan-Meier estimate of percentage of participants without a mortality event.Time to death due to any cause.
Time frame: Baseline to End of Study, approximately 86 months
Adjusted Percentage Ratio From Baseline in N-terminal Pro-B-type Natriuretic Peptide (NT-pro-BNP)
Blood sampling for the measurement of NT-pro-BNP was performed and the plasma concentrations of NT-pro-BNP were determined by a certified centralized laboratory.
Time frame: Baseline to Month 20
Change From Baseline to Week 16 in Borg Dyspnea Index
The Borg dyspnea index was evaluated immediately after the 6MWT to obtain a rating of dyspnea at the end of the exercise using a scale from 0 ('Nothing at all') to 10 ('Very, very severe - maximal').
Time frame: Baseline to Week 16
Change From Baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) Questionnaire Calculated Score
The EQ-5D questionnaire is a patient-reported outcome consisting of a 5 dimensional descriptive system and a visual analog scale (VAS). The descriptive system asks respondents to describe their health status. Health is defined in 5 dimensions: (1) mobility, (2) self care, (3) usual activities, (4) pain or discomfort, and (5) anxiety or depression. Each dimension is divided into 3 levels, indicating (a) no problem, (b) some or moderate problems, or (c) extreme problems. Respondents record their problem(s) in each of the 5 dimensions. Combinations of these levels define a total of 243 health states. A health state defined by the descriptive system of EQ-5D can be described by a 5-digit number with full health is indicated by 11111 and poorest health state by 33333. The EQ-5D calculated score was derived by re-assigning local scores for answers to each question and combining these local scores into a global score with ranges from 0 (worst possible outcome) to 1 (best possible outcome).
Time frame: From baseline to Week 16
Change From Baseline to Week 16 in the EuroQol 5 Dimensions (EQ-5D) Visual Analogue Scale Score
The EQ-5D questionnaire is a patient-reported outcome consisting of a 5 dimensional descriptive system and a visual analog scale (VAS) together with brief demographic questions. EQ-5D VAS asks respondents to rate their perception of their overall health on a vertical visual analogue scale with 'best imaginable health state' set at 100 and 'worst imaginable health state' set at 0.
Time frame: Baseline to Week 16
Patient Global Self Assessment (PGSA) Status at Week 16
The PGSA is a questionnaire that allows the patient to compare his/her PAH status in response to the question "How do you feel about your PAH today compared with your last visit?" asked by the investigator. Patients use a seven-point scale to respond: markedly better, moderately better, mildly better, no change, markedly worse, moderately worse, or mildly worse.
Time frame: Week 16
First subject, first visit was17 May 2006 and last subject, last visit was 05 Dec 2013.
| Milestone | Bosentan | Placebo |
|---|---|---|
| Started | 159 | 175 |
| Completed | 76 | 86 |
| Not completed | 83 | 89 |
| Withdrew: Death | 33 | 44 |
| Withdrew: Withdrawal of consent | 32 | 26 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Administrative reason | 7 | 7 |
| Withdrew: Decision by the investigator | 5 | 7 |
| Withdrew: Lung transplantation | 1 | 1 |
Kaplan-Meier estimate of percentage of participants without a morbidity/mortality event. A morbidity/mortality event is defined as the occurrence of a) death, b) hospitalization for worsening or complication of PAH or intravenous prostanoid initiation, c) atrial septostomy, d) lung transplantation, or e) worsening PAH, defined as "moderately" or "markedly" worsened PAH symptoms using a patient global self-assessment (PGSA) scale AND initiation of inhaled or subcutaneous prostanoids or the disease progression package (open-label bosentan). If a patient replied "no change" or "mildly worse" on the PGSA, a decrease in 6MWT of 20% versus last visit or 30% versus baseline is also required to confirm the event.
| percentage of participants-Kaplan Meier | Bosentan | Placebo |
|---|---|---|
| Kaplan-Meier estimate at Month 4 | 96.1 | 90.6 |
| Kaplan-Meier estimate at Month 8 | 90.5 | 83.0 |
| Kaplan-Meier estimate at Month 12 | 82.7 | 74.0 |
| Kaplan-Meier estimate at Month 16 | 74.7 | 71.0 |
| Kaplan-Meier estimate at Month 20 | 71.8 | 66.1 |
| Kaplan-Meier estimate at Month 24 | 66.6 | 61.5 |
| Kaplan-Meier estimate at Month 28 | 65.8 | 55.0 |
| Kaplan-Meier estimate at Month 32 | 62.4 | 52.7 |
| Kaplan-Meier estimate at Month 34 | 57.5 | 48.8 |
| Kaplan-Meier estimate at Month 40 | 56.4 | 48.0 |
| Kaplan-Meier estimate at Month 44 | 50.6 | 46.2 |
| Kaplan-Meier estimate at Month 48 | 46.7 | 45.2 |
| Kaplan-Meier estimate at Month 52 | 45.1 | 45.2 |
| Kaplan-Meier estimate at Month 56 | 45.1 | 42.6 |
| Kaplan-Meier estimate at Month 60 | 45.1 | 39.7 |
| Kaplan-Meier estimate at Month 64 | 45.1 | 39.7 |
| Kaplan-Meier estimate at Month 68 | 40.1 | 39.7 |
| Kaplan-Meier estimate at Month 72 | 40.1 | 39.7 |
| Kaplan-Meier estimate at Month 76 | 40.1 | 36.1 |
| Kaplan-Meier estimate at Month 80 | 40.1 | 36.1 |
| Kaplan-Meier estimate at Month 84 | 40.1 | 36.1 |
| Kaplan-Meier estimate at End of Study | 40.1 | 36.1 |
Kaplan-Meier estimate of percentage of participants without an event of death, hospitalization (for worsening or complication of PAH or initiation of intravenous prostanoids), atrial septostomy or lung transplantation. Time to first confirmed death, hospitalization (for worsening or complication of PAH or initiation of intravenous prostanoids), atrial septostomy or lung transplantation from baseline to end of study was confirmed by an independent Clinical Endpoint Committee.
| percentage of participants-Kaplan Meier | Bosentan | Placebo |
|---|---|---|
| Kaplan-Meier estimate at Month 4 | 97.4 | 95.3 |
| Kaplan-Meier estimate at Month 8 | 94.6 | 91.8 |
| Kaplan-Meier estimate at Month 12 | 89.6 | 88.8 |
| Kaplan-Meier estimate at Month 16 | 85.3 | 86.9 |
| Kaplan-Meier estimate at Month 20 | 82.3 | 83.8 |
| Kaplan-Meier estimate at Month 24 | 76.9 | 79.8 |
| Kaplan-Meier estimate at Month 28 | 76.1 | 74.7 |
| Kaplan-Meier estimate at Month 32 | 75.2 | 73.1 |
| Kaplan-Meier estimate at Month 36 | 72.2 | 64.4 |
| Kaplan-Meier estimate at Month 40 | 72.2 | 61.9 |
| Kaplan-Meier estimate at Month 44 | 64.2 | 60.1 |
| Kaplan-Meier estimate at Month 48 | 60.3 | 58.1 |
| Kaplan-Meier estimate at Month 52 | 57.4 | 56.8 |
| Kaplan-Meier estimate at Month 56 | 53.8 | 52.7 |
| Kaplan-Meier estimate at Month 60 | 53.8 | 51.3 |
| Kaplan-Meier estimate at Month 64 | 53.8 | 51.3 |
| Kaplan-Meier estimate at Month 68 | 39.8 | 49.2 |
| Kaplan-Meier estimate at Month 72 | 39.8 | 49.2 |
| Kaplan-Meier estimate at Month 76 | 39.8 | 45.1 |
| Kaplan-Meier estimate at Month 80 | 39.8 | 45.1 |
| Kaplan-Meier estimate at Month 84 | 39.8 | 45.1 |
| Kaplan-Meier estimate at End of Study | 39.8 | 45.1 |
The 6MWT is a non-encouraged test, which measures the distance covered over a 6 minute walk; the patient is instructed to walk as far as possible in a 30 m long flat corridor, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Areas were to be well ventilated with air temperature controlled between 20 °C and 23 °C (68 °F to 76 °F). The test was to be administered at the same time of day and by the same tester throughout the study. The tester measured the distance walked by non-encouraged patients during the timed 6 minute period.
| m | Bosentan | Placebo |
|---|---|---|
| Baseline | 363 ± 78.5 | 358 ± 73.1 |
| Week 16 | 370 ± 98.3 | 343 ± 107.3 |
| Change from baseline | 7.2 ± 66.01 | -14.6 ± 80.42 |
Class I: no limitation of usual physical activity (PA) which does not increase dyspnea, fatigue, chest pain, or presyncope. Class II: mild limitation of PA. No discomfort at rest. Normal PA increases dyspnea, fatigue, chest pain, or presyncope. Class III: marked limitation of PA. No discomfort at rest. Less than ordinary activity increases dyspnea, fatigue, chest pain, or presyncope. Class IV: unable to perform any PA and who may have signs of right ventricular failure. Dyspnea and/or fatigue may be present at rest and symptoms are increased by almost any PA.
| participants | Bosentan | Placebo |
|---|---|---|
| Improved | 25 | 28 |
| No change | 121 | 130 |
| Worsened | 13 | 17 |
Kaplan-Meier estimate of percentage of participants without a mortality event.Time to death due to any cause.
| percentage of participants-Kaplan Meier | Bosentan | Placebo |
|---|---|---|
| Kaplan-Meier estimate at Month 4 | 99.4 | 98.2 |
| Kaplan-Meier estimate at Month 8 | 98.7 | 95.8 |
| Kaplan-Meier estimate at Month 12 | 96.5 | 94.0 |
| Kaplan-Meier estimate at Month 16 | 92.8 | 92.8 |
| Kaplan-Meier estimate at Month 20 | 90.6 | 89.5 |
| Kaplan-Meier estimate at Month 24 | 89.1 | 88.2 |
| Kaplan-Meier estimate at Month 28 | 85.8 | 85.9 |
| Kaplan-Meier estimate at Month 32 | 85.8 | 84.3 |
| Kaplan-Meier estimate at Month 36 | 85.8 | 78.5 |
| Kaplan-Meier estimate at Month 40 | 85.8 | 76.8 |
| Kaplan-Meier estimate at Month 44 | 81.4 | 74.9 |
| Kaplan-Meier estimate at Month 48 | 77.7 | 71.8 |
| Kaplan-Meier estimate at Month 52 | 75.0 | 70.5 |
| Kaplan-Meier estimate at Month 56 | 70.1 | 66.4 |
| Kaplan-Meier estimate at Month 60 | 67.8 | 64.9 |
| Kaplan-Meier estimate at Month 64 | 67.8 | 64.9 |
| Kaplan-Meier estimate at Month 68 | 67.8 | 64.9 |
| Kaplan-Meier estimate at Month 72 | 67.8 | 64.9 |
| Kaplan-Meier estimate at Month 76 | 67.8 | 60.3 |
| Kaplan-Meier estimate at Month 80 | 58.1 | 60.3 |
| Kaplan-Meier estimate at Month 84 | 58.1 | 60.3 |
| Kaplan-Meier estimate at End of Study | 58.1 | 60.3 |
Blood sampling for the measurement of NT-pro-BNP was performed and the plasma concentrations of NT-pro-BNP were determined by a certified centralized laboratory.
| Adjusted percentage ratio from baseline | Bosentan | Placebo |
|---|---|---|
| Month 1 to Baseline | 87.46 (77.12 to 99.18) | 110.02 (97.56 to 124.06) |
| Month 4 to Baseline | 92.65 (81.20 to 105.72) | 113.20 (99.61 to 128.65) |
| Month 8 to Baseline | 85.21 (72.58 to 100.05) | 122.87 (104.82 to 144.02) |
| Month 12 to Baseline | 84.48 (71.48 to 99.83) | 132.11 (111.95 to 155.89) |
| Month 16 to Baseline | 92.69 (75.75 to 113.42) | 129.92 (106.69 to 158.20) |
| Month 20 to Baseline | 98.36 (79.46 to 121.75) | 143.17 (115.86 to 176.91) |
| Treatment effect over 20 months | 92.54 (82.72 to 103.52) | 121.00 (108.42 to 135.05) |
The Borg dyspnea index was evaluated immediately after the 6MWT to obtain a rating of dyspnea at the end of the exercise using a scale from 0 ('Nothing at all') to 10 ('Very, very severe - maximal').
| units on a scale | Bosentan | Placebo |
|---|---|---|
| Baseline | 3.5 ± 1.99 | 3.7 ± 2.18 |
| Week 16 | 3.4 ± 2.12 | 3.6 ± 2.24 |
| Change from baseline | -0.09 ± 1.693 | -0.08 ± 2.035 |
The EQ-5D questionnaire is a patient-reported outcome consisting of a 5 dimensional descriptive system and a visual analog scale (VAS). The descriptive system asks respondents to describe their health status. Health is defined in 5 dimensions: (1) mobility, (2) self care, (3) usual activities, (4) pain or discomfort, and (5) anxiety or depression. Each dimension is divided into 3 levels, indicating (a) no problem, (b) some or moderate problems, or (c) extreme problems. Respondents record their problem(s) in each of the 5 dimensions. Combinations of these levels define a total of 243 health states. A health state defined by the descriptive system of EQ-5D can be described by a 5-digit number with full health is indicated by 11111 and poorest health state by 33333. The EQ-5D calculated score was derived by re-assigning local scores for answers to each question and combining these local scores into a global score with ranges from 0 (worst possible outcome) to 1 (best possible outcome).
| units on a scale | Bosentan | Placebo |
|---|---|---|
| Baseline | 0.678 ± 0.2172 | 0.681 ± 0.2138 |
| Week 16 | 0.662 ± 0.2807 | 0.645 ± 0.3062 |
| Change from Baseline | -0.0161 ± 0.25232 | -0.0361 ± 0.26671 |
The EQ-5D questionnaire is a patient-reported outcome consisting of a 5 dimensional descriptive system and a visual analog scale (VAS) together with brief demographic questions. EQ-5D VAS asks respondents to rate their perception of their overall health on a vertical visual analogue scale with 'best imaginable health state' set at 100 and 'worst imaginable health state' set at 0.
| units on a scale | Bosentan | Placebo |
|---|---|---|
| Baseline | 67 ± 17.4 | 64 ± 17.5 |
| Week 16 | 69 ± 19.9 | 66 ± 19.9 |
| Change from Baseline | 2.1 ± 18.83 | 2.0 ± 17.01 |
The PGSA is a questionnaire that allows the patient to compare his/her PAH status in response to the question "How do you feel about your PAH today compared with your last visit?" asked by the investigator. Patients use a seven-point scale to respond: markedly better, moderately better, mildly better, no change, markedly worse, moderately worse, or mildly worse.
| participants | Bosentan | Placebo |
|---|---|---|
| Markedly better | 24 | 13 |
| Moderately better | 23 | 30 |
| Mildly better | 32 | 36 |
| No change | 50 | 59 |
| Mildly worse | 16 | 15 |
| Moderately worse | 3 | 5 |
| Markedly worse | 2 | 4 |
Collected over Up to End of Study and up to 1 day after discontinuation of study treatment, approximately 86 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bosentan | — | 73/159 (45.9%) | 135/159 (84.9%) |
| Placebo | — | 102/174 (58.6%) | 147/174 (84.5%) |
| Event | Bosentan | Placebo |
|---|---|---|
| PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 25/159 | 28/174 |
| PNEUMONIAInfections and infestations | 11/159 | 6/174 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 5/159 | 8/174 |
| RIGHT VENTRICULAR FAILURECardiac disorders | 6/159 | 8/174 |
| CHEST PAINGeneral disorders | 5/159 | 7/174 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 6/159 | 3/174 |
| BRONCHITISInfections and infestations | 6/159 | 3/174 |
| SYNCOPENervous system disorders | 3/159 | 6/174 |
| GASTROENTERITISInfections and infestations | 3/159 | 5/174 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 4/159 | 2/174 |
| Event | Bosentan | Placebo |
|---|---|---|
| PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 15/159 | 35/174 |
| OEDEMA PERIPHERALGeneral disorders | 30/159 | 26/174 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 21/159 | 29/174 |
| HEADACHENervous system disorders | 24/159 | 24/174 |
| COUGHRespiratory, thoracic and mediastinal disorders | 22/159 | 21/174 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 21/159 | 19/174 |
| NAUSEAGastrointestinal disorders | 16/159 | 22/174 |
| BACK PAINMusculoskeletal and connective tissue disorders | 15/159 | 22/174 |
| DIARRHOEAGastrointestinal disorders | 19/159 | 19/174 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 13/159 | 20/174 |
All randomized set
| Age, Continuous(years) | Bosentan | Placebo | Total |
|---|---|---|---|
| Mean | 52.9 ± 15.44 | 54.7 ± 15.73 | 53.9 ± 15.60 |
| Sex: Female, Male(Participants) | Bosentan | Placebo | Total |
|---|---|---|---|
| Female | 125 | 128 | 253 |
| Male | 34 | 47 | 81 |
| Race/Ethnicity, Customized(participants) | Bosentan | Placebo | Total |
|---|---|---|---|
| Caucasian/White | 147 | 149 | 296 |
| Black | 7 | 12 | 19 |
| Hispanic | 5 | 6 | 11 |
| Other | 0 | 8 | 8 |
| Region of Enrollment(participants) | Bosentan | Placebo | Total |
|---|---|---|---|
| Brazil | 36 | 35 | 71 |
| Czech Republic | 12 | 15 | 27 |
| Denmark | 3 | 4 | 7 |
| Germany | 19 | 22 | 41 |
| Greece | 4 | 5 | 9 |
| Portugal | 3 | 0 | 3 |
| Saudi Arabia | 0 | 1 | 1 |
| Slovakia | 4 | 3 | 7 |
| Spain | 1 | 1 | 2 |
| Sweden | 4 | 5 | 9 |
| United Kingdom | 0 | 1 | 1 |
| United States | 73 | 83 | 156 |
No study locations are listed for this record.
The record gives a start of May 2006, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan
Pulmonary Arterial Hypertension →